Dr Tanwar has published widely in peer reviewed international journals and textbooks on a broad range of subjects such as diagnostic testing, Endoscopy, HPB medicine, Hepatitis, Inflammatory Bowel Disease, anaemia and gastrointestinal malignancy.

​

Dr Tanwar attained his PhD from the prestigious Institute for Liver & Digestive Health within the Division of Medicine at University College London (UCL) and now works as an Honorary Associate Professor at this institution. 

​

Original Articles, Reviews and Letters

The fate of indeterminate liver lesions: What proportion are precursors of hepatocellular carcinoma?

Cococcia S, Dutta P, Moghim M, Hogan B, Tanwar S, Marshall A, Macdonald D, Yu D, O'Beirne J, Rosenberg W, Trembling P

BMC Gastroenterol . 2022 Mar 10;22(1):118.

doi: 10.1186/s12876-022-02135. PMID: 35272611

​

The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.

Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J, Burt A, Watkins J, Sievert W, Rosenberg W.

BMC Gastroenterol. 2021 Jun 28;21(1):268.

doi: 10.1186/s12876-021-01795-5.PMID: 34182924 

​

Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests.

Rhodes FA, Cococcia S, Patel P, Panovska-Griffiths J, Tanwar S, Westbrook RH, Rodger A, Rosenberg W.

BMJ Open. 2021 Jun 4;11(6):e047786.

doi: 10.1136/bmjopen-2020-047786. PMID: 34088709 

​​

Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test

Rhodes F, Cococcia S, Panovska-Griffiths J, Tanwar S, Westbrook RH, Rodger A, Rosenberg WM.

BMC Gastroenterol. 2021 Mar 31;21(1):143.

doi: 10.1186/s12876-021-01728-2.PMID: 33789586 

​

Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

Rhodes AF, Trembling P, Panovska-Griffiths J, Tanwar S, Westbrook R, Rodger A, Rosenberg W.
J Gastroenterol Hepatol​ 2020 Nov 10

doi: 10.1111/jgh.15335.  PMID: 33171534

​

Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.

Tanwar S, Srivastava A, Rosenberg W.

J Hepatol. 2020 Sep 26:S0168-8278(20)30462-1.

doi: 10.1016/j.jhep.2020.07.009. PMID: 32994080 

​

The Enhanced Liver Fibrosis Test Is Associated With Liver-Related Outcomes in Postmenopausal Women With Risk Factors for Liver Disease .

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM.

BMC Gastroenterol. 2020 Apr 15;20(1):104.

doi: 10.1186/s12876-020-01251-w. PMID: 32293289

 

After the introduction of EUS-guided drainage, is there still a role for endoscopic transpapillary gallbladder stent placement for patients who are not fit for cholecystectomy?

Phillpotts S, Tanwar S

Gastrointestinal Endoscopy 2020 April;91(4):957-958.

doi: 10.1016/j.gie.2019.11.033. PMID: 32204821

​

Haemobilia in a previously stented hilar cholangiocarcinoma: successful haemostasis after the insertion of fcSEMS.

Tien T, Tan  YC , Baptiste P, Tanwar S

Oxf Med Case Reports. 2020 Feb; 2020(2): omaa010.

doi: 10.1093/omcr/omaa010. PMID: 32128221

​

Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C .

Tanwar S, Rhodes F, Srivastava A, Trembling P, Rosenberg W

World J Gastroenterol. Jan 14, 2020; 26(2): 109-133.

doi: 10.3748/wjg.v26.i2.109. PMID: 31969775

​

Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.

Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W.

BMC Gastroenterol. 2019 Jul 11;19(1):122.

doi: 10.1186/s12876-019-1039-4. PMID: 3129616

​

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

Srivastava A,  Gailer A, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D,  Sennett K,  Morgan S, Tsochatzis E, Rosenberg W

J Hepatol. 2019 Aug;71(2):371-378.

doi: 10.1016/j.jhep.2019.03.033. PMID: 30965069

​

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

PMID: 29995365

​

Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS).

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Menon U, Rosenberg WM.

BMC Public Health. 2018 Mar 27;18(1):409.

doi: 10.1186/s12889-018-5308-x. PMID: 29587697

​

Covered self-expanding metal stents: a promising therapy for difficult stone disease

Phillpotts S, Ardley C, Christodoulou C, Tanwar S

Gastrointestinal Endoscopy 2017 Dec;86(6):1188.

PMID 29146086 Doi:10.1016/j.gie.2017.06.002

​

Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOKS)

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Jacobs I, Menon U, Rosenberg W

BMC Public Health 2017 Jun 28;17(1):603. doi:10.1186/s12889-017-4518-y. 

PMID: 28659136

​

The Enhanced Liver Fibrosis (ELF) Panel: analyte stability under common sample storage conditions used in clinical practice.

Kennedy O, Parkes J, Tanwar S, Trembling P, Rosenberg WM

Applied Laboratory Medicine May 2017, 1 (6) 720-728

doi:101.1373/jalm.2016.022806

​​

Ingestion of cylindrical batteries and its management

Tien T, Tanwar S

BMJ Case Reports 2017 Jan 17;2017.pii: bcr2016218448

PMID: 28096228

​​

Noninvasive markers of liver fibrosis: on treatment changes of direct markers predict the outcome of anti-fibrotic therapy

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM

Eur J Gastroenterol Hepatol 2017 Mar;29(3):289-296

PMID: 27906753

​​

Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: a comparison of 10 biomarkers using 2 different assays for Hyaluronic Acid

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM

J Clin Gastroenterol 2017 Mar; 51(3):268-277

PMID:27380461

​​

Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure.

Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T

Antiviral Res. 2014 May;105:112-7. doi: 10.1016/j.antiviral.2014.02.019.

PMID: 24594347

​​

Complexities of HCV management in the new era of direct-acting antiviral agents.

Rosenberg WM, Tanwar S, Trembling P

QJM 2013 Sept23

PMID:24065837

​​

Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.

Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM

Journal of Viral Hepatitis, 2013, 21: 430–438.

doi: 10.1111/jvh.12161

​​

Treatment decisions and contemporary versus pending treatments for hepatitis C.

Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM.

Nat Rev Gastroenterol Hepatol. 2013

doi: 10.1038/nrgastro.2013.163.

​

The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells.

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK

PLoS One. 2013 Aug 8;8(8):e72188.

doi: 10.1371/journal.pone.0072188. PMID: 23951294

​

Validation of PIIINP for the detection and assessment of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2013 Jan;57(1):103-11.

doi: 10.1002/hep.26030. PMID: 22930399

​

Hepatitis C Therapy: Lessons of the Last Two Decades.

Tanwar S, Trembling PM, Dusheiko GM.

Curr Hepatitis Rep 2012 11:119–127

doi:10.1007/s11901-012-0141-7

​

TMC435 for the treatment of chronic hepatitis C.

Tanwar S, Trembling PM, Dusheiko GM.

Expert Opin Investig Drugs. 2012 Aug;21(8):1193-209.

doi: 10.1517/13543784.2012.690392. PMID: 22397560

​

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.

Trembling PM, Tanwar S, Dusheiko GM.

Expert Rev Anti Infect Ther. 2012 Mar;10(3):269-79.

doi: 10.1586/eri.12.8. PMID: 22397560

​

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50.

doi: 10.1097/MEG.0b013e3283513e69. PMID: 22337287

​

Protease inhibitors for chronic hepatitis C: management of side effects.

Trembling PM, Tanwar S, Dusheiko GM.

Hot Topics In Viral Hepatitis: Issue 25, 2012.

doi: 10.4147/HTV-122519

​

Is there any value to hepatitis B virus genotype analysis?

Tanwar S, Dusheiko G

Curr Gastroenterol Rep. 2012 Feb;14(1):37-46.

doi: 10.1007/s11894-011-0233-5. PMID: 22105466

​

Granulocyte colony stimulating factor as a novel adjunct to improve Hepatitis B Vaccine response

Tanwar S, Thurz M

World J Hepatol 2010 March 27; 2(3): 136-138.

doi: 10.4254/wjh.v2.i3.136. PMID: 21160984

​

Liver Transplantation for Hepatocellular Carcinoma.

Tanwar S, Khan SA, Grover VP, Gwilt C, Smith B, Brown A.

World J Gastroenterol 2009 November 28; 15(44): 5511-5516.

PMID: 19938188

​

What to do if standard therapy for hepatitis C fails.

Tanwar S, Khakoo S.

F1000 Medicine Reports 2009, 1:41.

PMID: 20052398

​

Successful Endoscopic Management of Bouveret's Syndrome in a Patient with Cholecystoduodenocolic Fistulae

Tanwar S, Mawas A, Tutton M, O'Riordan D

Case Rep Gastroenterol 2008;2:346-350.

doi: 10.1159/000151581. doi: 10.1159/000151581.

​

Primary presentation of oesophageal adenocarcinoma as brain metastasis – a case report.

Tanwar S, Barton SGR.

Gastroenterology Today 2005; Volume 15, Issue 3: 73-74.

http://www.gastroenterologytoday.com/Issues/GT3_05/Tanwar%20S,%20Barton%20SG.pdf

​

 

Book Chapters

​

Tietz Text book of Clinical Chemistry & Molecular Diagnostics

“Liver Disease”

 Professor William Rosenberg and Dr Sudeep Tanwar

​

 Advanced Medicine:

“Treatment of Hepatitis B in the 21st-century”

Professor William Rosenberg and Dr Sudeep Tanwar

​

Selected Published Abstracts

                                                      

The combination of ABIC+ELF as a single marker outperforms ABIC alone in predicting 90-day survival in alcoholic hepatitis.

Rhodes F, Vergis N, Thursz M, The STOPAH Trial Group, Westbrook RH, Rodger A, Tanwar S, Rosenberg W

EASL Annual Meeting 2021

​

An algorithm combining Hyaluronic acid, Procollagen III amino-terminal peptide (PIIINP) and the Glasgow Alcoholic Hepatitis Score in a single number predicts 90-day mortality in alcohol-related hepatitis.

Rhodes F, Cococcia S, Vergis N, Thursz M, Atkinson S, The STOPAH Trial Group, Tanwar S, Rosenberg W

BASL annual meeting 2019

​

Successful ERCP in a patient with peri-hilar stenting in a patient with Situs Inversus - a UK first

Green C, Gananandan K, Tanwar S

Gut. BSG annual meeting 2019

​

Efficacy of FCSEMS for refractory CBD stones at a single centre over a 3 year period

Green C, Gananandan K, Phillpotts S, El=Sherif Y, Tanwar S

Gut. BSG annual meeting 2019

​

Successful endoscopic closure of duodenal ulcer perforation using OTSC in a frail patient unsuitable for surgery

Sutherland M, Green C, Gananandan K, Tanwar S

Gut. BSG annual meeting 2019

​

Enhanced Liver Fibrosis test utility in alcoholic liver disease

Connoley D, Patel P, Hogan B, Tanwar S, Rhodes F, Parkes J, Sievert W, Rosenberg W

J Hepatol. EASL Annual Meeting 2019

 

Endoscopic closure of large spontaneous periampullary duodenal diverticular retroperitoneal perforation using 3 padlock clips after biliary stent placement.

Iqbal J., Todd J., El-Sherif Y., Tanwar S.

UEGW Meeting 2018

​

Novel endoscopic treatment of 3.5 cm Periampullary duodenal perforation using Padlock clips 49 days after unsuccessful surgery

Iqbal J., Todd J., El-Sherif Y., Tanwar S.

UEGW Meeting 2018

​

Endoscopic closure of anterior resection anastomotic dehiscence using Padlock clips

Iqbal J., Tariq A, Tanwar S.

Gut. BSG Annual Meeting 2018

​

Real-world performance of non-invasive imaging modalities in the detection of common bile duct stones (CBDS)

Iqbal J., Giles B, Palmer-Jones C, Crinnion W, Syed Muhammad, Tanwar S

Gut. BSG Annual Meeting 2018

​

Introduction of SEMS for malignant distal biliary strictures at a large London District General Hospital

Dean E, Bain L, Tanwar S

Gut. BSG Annual Meeting 2018

​

Endoscopic Transpapillary Gallbladder Stenting (ETGS) for patients unsuitable for cholecystectomy: prospective single centre case series

Philpotts S, Iqbal J, Christodoulou C, Rohatgi A, Tanwar S

Gut. BSG Annual Meeting 2018

​

Enhanced liver fibrosis test predicts liver-related outcomes in postmenopausal women with risk factors in the community

Journal of Hepatology, Volume 68, Supplement 1, April 2018, Page s641

P. Trembling, S Tanwar. Apostolidou, A. Gentry-Maharaj, J. Parkes, W. Rosenberg

​

Ingestion of 3 cylindrical Batteries and its Management

International Surgical Congress 2017

Tien T, Tanwar S

​

Minimising ERCP Remuneration Losses by Improving Coding Accuracy: An Eight Month Quality Improvement Project

Phillpotts S, Hooper H, Jobling S, Tanwar S

Gut 2017. (BSG Annual Meeting 2017)

​

Primary Care Sequential Use of FIB-4 and the Enhanced Liver Fibrosis Test to stratify patients with NAFLD doubles cirrhosis detection and reduced referrals of patients with mild disease

Srivastava A, Gallier R, Demma A, Warner D, Suri D, Morgan S, Tanwar S, Sennett K, Thorburn D, Parkes E, Tsochatzis E, Rosenberg W

J Hepatol 2016 (EASL Annual Meeting 2016)

​

Designing enhanced pathways of care for patients with chronic hepatitis B using Hepbase, a proprietary database used to stratify patients

Srivastava A, Trembling P, Tanwar S, Catt J, Mehmoob Z, Morgan D, Dusheiko G, Rosenberg W

J Hepatol 2015 (EASL Annual Meeting 2015)

​

A one year retrospective review of new patient attendances at a tertiary hepatology centre highlighting the increasing challenge of NAFLD and the need to develop clinical pathways

Srivastava A, Gallier R, Tanwar S, Trembling P, Warner A, Morgan S, Sennett K, Thorburn D, Tsochatzis E, Rosenberg W

J Hepatol 2015 (EASL Annual Meeting 2015)

​

Known unknowns: chronic liver disease (CLD) in primary care detected with abnormal aminotransferase and normal liver ultrasound; aetiology, severity and prognosis.

Tanwar S, Parkes J, Trembling PM, Hogan B, Thorburn D, Schuppan D, Pinzani M, Burt AD, Rosenberg WM.

Gut 2013 (BASL Annual Meeting 2013)

​

Further Validation of Terminal Peptide of Procollagen III (PIIINP) for the Detection and Assessment of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease.

Tanwar S, Parkes J, Trembling PM, Hogan B, Schuppan D, Pinzani M, Arthur M, Burt AD, Rosenberg WM.

J Hepatol 2013 (EASL Annual Meeting 2013)

​

Treatment of patients with chronic hepatitis C genotype 1 and advanced fibrosis with protease inhibitors- IL28B discordance results in early viral decline but late relapse.

Tanwar S, Trembling P, Hogan  B,  Catt J,  Glasgow S, Glover N, Ju M, Hains M,  Moore MT, Velazquez C, Conibear T, Labbett W, Irish D,  Macartney M, Haque T, Nastouli E, Smith B, Smith P, Suri D, Oben JA, Jacobs MG, Dusheiko GM, Rosenberg WM.

Gut 2013 (BSG Annual Meeting 2013)

​

Comparison of 4 serum marker panels of fibrosis in chronic hepatitis c (CHC): variants of the hyaluronic acid assay significantly effect their diagnostic performance.

Tanwar S, Trembling PM, Hogan B, Ellis E, Parkes J, Herold C, Schuppan D, Rosenberg WM

Gut 2013 (BSG Annual Meeting 2013)

​

An algorithm combining direct and indirect panels for fibrosis can result in enhanced diagnostic performance for the detection of advanced fibrosis (F3-4) in NAFLD thus minimising the need for liver biopsy

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology 2012 (AASLD Annual Meeting 2012)

​

Host and viral factors predicting response to protease inhibitors - a prospective cohort of 51 patients with chronic hepatitis C and advanced fibrosis treated with pegylated interferon-alfa and ribavirin and either telaprevir or boceprevir at a single centre

Tanwar S, Trembling PM, Hogan B, Catt J, Glasgow S, Winter S, Ju M, Moore MT, Hains M, Velazquez C, Macartney M, Irish D, Haque T, Smith B, Suri D, Jacobs MG, Dusheiko GM, Rosenberg WM

 Best Practice for G1 Hepatitis C Patients 2012, London, UK.

​

Direct non-invasive serum markers of liver fibrosis predict fibrosis evolution in chronic hepatitis C but are increased by Interferon-based therapy.

Tanwar S, Trembling PM, Ellis E, Parkes J, Herold C, Schuppan D, Rosenberg WM

J Hepatol 2012 (EASL Annual Meeting 2012)

​

Direct serum markers are more accurate than simple marker panels for the detection of fibrosis in non-alcoholic fatty liver Disease (NAFLD).

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

J Hepatol 2012 (EASL Annual Meeting 2012)

​

Do All Arterialised Nodules Become Hepatocellular Carcinoma? The Outcome Of 4 Years Magnetic Resonance Imaging Surveillance

Journal of Hepatology, Volume 56, Supplement 2, April 2012, Page s282

Hogan B, Trembling P, Tanwar S, Yu D, Rosenberg W

​

Validation of a novel biomarker model for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology 2011 (AASLD Annual Meeting 2011)

 

Daily Radiology Consultant Ward Round in Acute Medical Unit Prevents ‘Missed’ Diagnoses

Tanwar S, Wong J, Morley A, Howell D.

International Forum of Quality and Safety in Healthcare 2011, Amsterdam, Netherlands.

​

Comparison of enhanced liver fibrosis test and transient elastography for the non-invasive assessment of liver fibrosis in chronic hepatitis B. 

Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM.

Hepatology 2011 (AASLD Annual Meeting 2011)

​

Changes in ELF score during treatment with Pegylated Interferon and Silymarin are associated with histological liver disease progression in non-responder patients with chronic hepatitis C.

Tanwar S, Trembling PM, Ellis E, Parkes J, Herold C, Rosenberg WM

Journal of Hepatology, March 2011,Vol. 54 Supplement 1, page S55 (EASL Annual Meeting 2011)

​

The prevalence of iron deficiency and anemia in a cross sectional study of ambulatory patients with inflammatory bowel disease in a tertiary referral centre.

Tanwar S, Lipman G, Parkes J, McCartney S.

Gut 2010;59:A17-A18 doi:10.1136/gut.2010.223362.41. (BSG Annual Meeting 2010)

​

Non-invasive assessment of hepatic fibrosis in prior non-responders to HCV treatment- a comparison of 8 marker panels of liver fibrosis.

Tanwar S, Ellis E, Parkes J, Herold C, Rosenberg WM

Hepatology 2010 (AASLD Annual Meeting 2010)

​

PACIFIC: A phase III, randomized, multicenter, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child’s A or B cirrhosis in chronic hepatitis C virus infection.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Hepatology Volume 52, Issue S1, pages 1292A–1340A, October 2010 (AASLD Annual Meeting 2010)

​